Bcworldpharm

비씨월드제약 · 200780

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$29M (₩40B)

Overview

Bcworldpharm makes prescription medicines, drugs used to treat, prevent, and manage a range of diseases, and supplies them to domestic pharmaceutical companies as well as exporting to markets across Europe, Latin America, the Middle East, CIS countries, and Asia.

Listed on KOSDAQ, Korea's small-cap and technology board, it serves both end-market customers and other drug makers that outsource manufacturing. Beyond its own branded products, the company operates contract manufacturing (CMO) and contract development-and-manufacturing (CDMO) businesses, and is also pursuing overseas licensing of its in-house research and development technology.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$54.9M
▲ +1.3% YoY
Operating profit · FY2025
US$1.4M
▲ +33.1% YoY
Net income · FY2025
−US$2.3M
Loss narrowed

Revenue

  • FY2023US$54.4M
  • FY2024US$54.2M
  • FY2025US$54.9M

Operating profit

  • FY2023US$4.6M
  • FY2024US$1.1M
  • FY2025US$1.4M

Net income

  • FY2023US$2.1M
  • FY2024−US$2.4M
  • FY2025−US$2.3M

Key ratios (FY2025)

ROE
-4.3%
Debt/Eq
143.9%
Op. margin
2.6%
Net margin
-4.2%
Rev. YoY
▲ +1.3%

Why it matters

Bcworldpharm consolidates two subsidiaries, 비씨월드헬스케어, a prescription-drug maker, and 하트애드, an advertising agency, into its group financial statements.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.